LeonaBio (LONA) Net Income (2019 - 2026)
LeonaBio (LONA) posted quarterly Net Income of -$21.1 million for Q1 2026, down 96.12% year-over-year from -$543.5 million in Q1 2025, and up 73.81% quarter-over-quarter from -$80.6 million in Q4 2025.
LeonaBio (LONA) Net Income (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Net Income for 8 consecutive years, with -$21.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 96.12% year-over-year to -$21.1 million; the TTM figure through Mar 2026 stood at -$118.0 million (up 33.75% YoY), while the FY2025 annual figure was -$105.6 million, down 8.98% from the prior year.
- Net Income advanced to -$21.1 million in Q1 2026 per LONA's latest filing, from -$80.6 million in the prior quarter.
- Across five years, Net Income topped out at -$7.9 million in Q3 2025 and bottomed at -$107.5 million in Q4 2024.
- Historically, Net Income has averaged -$33.8 million across 5 years, with a median of -$29.4 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income plunged 265.68% — and 2025, when it surged 74.74%.
- LeonaBio's Net Income stood at -$33.3 million in 2022, then grew by 11.77% to -$29.4 million in 2023, then slumped by 265.68% to -$107.5 million in 2024, then climbed by 25.04% to -$80.6 million in 2025, then jumped by 73.81% to -$21.1 million in 2026.
- Business Quant data shows LONA's Net Income at -$21.1 million in Q1 2026, -$80.6 million in Q4 2025, and -$7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | -19.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.11 Mn |
| Dec 31, 2025 | -80.60 Mn |
| Sep 30, 2025 | -7.86 Mn |
| Jun 30, 2025 | -8.40 Mn |
| Mar 31, 2025 | -10.76 Mn |
| Dec 31, 2024 | -107.52 Mn |
| Sep 30, 2024 | -31.09 Mn |
| Jun 30, 2024 | -28.68 Mn |
| Mar 31, 2024 | -29.40 Mn |
| Dec 31, 2023 | -29.40 Mn |
| Sep 30, 2023 | -36.99 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -31.95 Mn |
| Dec 31, 2022 | -33.32 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -24.36 Mn |
| Mar 31, 2022 | -33.52 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -23.83 Mn |
| Jun 30, 2021 | -24.34 Mn |